TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

PHARMACYCLICS LLC

OncologyGastroenterology
Specialty

PHARMACYCLICS LLC is a specialty pharmaceutical company focused on Oncology, Gastroenterology. Key products include IMBRUVICA.

2013
Since
1
Drugs
-
Trials
9
Approved (2yr)

Key Drugs

IMBRUVICA
ibrutinib
Oncology
BTK 5 indications · 2013

Recent Activity

IMBRUVICA 2025-10-21
Labeling
IMBRUVICA 2025-10-21
Labeling
IMBRUVICA 2025-10-21
Labeling
IMBRUVICA 2024-12-20
Labeling
IMBRUVICA 2024-12-20
Labeling
IMBRUVICA 2024-12-20
Labeling
IMBRUVICA 2024-05-09
Labeling
IMBRUVICA 2024-05-09
Labeling
IMBRUVICA 2024-05-09
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 95%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 4
Gastroenterology 5%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology